Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

Inhibikase Therapeutics (IKT) Long-Term Debt Repayments (2021 - 2022)

Historic Long-Term Debt Repayments for Inhibikase Therapeutics (IKT) over the last 2 years, with Q1 2022 value amounting to $248911.0.

  • Inhibikase Therapeutics' Long-Term Debt Repayments fell 3923.99% to $248911.0 in Q1 2022 from the same period last year, while for Dec 2022 it was $248911.0, marking a year-over-year increase of 48520.48%. This contributed to the annual value of $248911.0 for FY2022, which is 48520.48% up from last year.
  • As of Q1 2022, Inhibikase Therapeutics' Long-Term Debt Repayments stood at $248911.0, which was down 3923.99% from -$367128.0 recorded in Q2 2021.
  • In the past 5 years, Inhibikase Therapeutics' Long-Term Debt Repayments registered a high of $409662.0 during Q1 2021, and its lowest value of -$367128.0 during Q2 2021.